N/A
Manufactured by Aurobindo Pharma Limited
40,073 FDA adverse event reports analyzed
Last updated: 2026-04-14
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) include URINARY TRACT INFECTION, FATIGUE, NAUSEA, HEADACHE, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS).
Out of 15,935 classified reports for NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS):
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.